clear-rite 3 (Fisher Scientific)
90
Structured Review
Fisher Scientific
clear-rite 3
Clear Rite 3, supplied by Fisher Scientific, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/clear-rite-3/clear+rite+3/pmc11416640-86-0-4
Average 90 stars, based on 1 article reviews
Clear Rite 3, supplied by Fisher Scientific, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/clear-rite-3/clear+rite+3/pmc11416640-86-0-4
Average 90 stars, based on 1 article reviews
clear-rite 3 - by Bioz Stars,
2026-10
90/100 stars
Images
Related Articles
other:Article Title: Protocol to establish an accelerated murine model for Helicobacter -induced gastric cancer Article Snippet: Epredia Clear-Rite 3 , Fisher Scientific , 69-05. Article Title: Bioactive Polyurethane Shape Memory Polymer Foam Dressings with Enhanced Blood and Cell Interactions for Improved Wound Healing. Article Snippet: Foam sections cut from the proximal, middle, and distal end of the foams were removed from 4% formalin, dehydrated in increasing concentrations of ethanol (70% to 100%), and cleared with Epredia Signature Series Clear-Rite 3 (Fisher Scientific, Hampton, NH) using the Epredia STP 120 Spin Tissue Processor (Epredia, Kalamazoo, MI). Staining:Article Title: Spatially patterned 3D model mimics key features of cancer metastasis to bone. Article Snippet: Bone is the most common target of metastasis in breast cancer and prostate cancer, leading to significant mortality due to lack of effective treatments.. The discovery of novel therapies has been hampered by a lack of physiologically relevant in vitro models that can mimic key clinical features of bone metastases.. To fill this critical gap, here we report spatially patterned, tissue engineered 3D models of breast cancer and prostate cancer bone metastasis which mimic bone-specific invasion, cancer aggressiveness, cancer-induced dysregulation of bone remodeling, and in vivo drug response. |